Danish Medicines Council rejects Johnson & Johnson's psoriasis medicine: "Worse than existing standard treatment"

Tremfya will not be becoming the standard treatment for psoriatic arthritis, a type of arthritis which can accompany the inflammatory skin disease.
Photo: BRENDAN MCDERMID/REUTERS / X90143
Photo: BRENDAN MCDERMID/REUTERS / X90143
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY CATHERINE BRETT

The Danish Medicines Council has refused to recommend Johnson & Johnson's drug Tremfya as the standard treatment for psioratic arthritis in Denmark - no matter how it is priced.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading